Comunicati Stampa
Salute e Benessere

Immunovia completes analytical validation of its next-generation pancreatic cancer test

Key highlights of the analytical validation include,  Key highlights of the analytical validation include,  The analytical validation was conducted using an automated ELISA analyzer, which significantly enhances both performance and throughput compared to Immunovia's prior IMMray platform as well as standard manual ELISA tests.  "We are happy to announce that our analytical validation results confirm the strong performance of our next-generation test.  This achievement validates the...
LUND, Sweden, (informazione.it - comunicati stampa - salute e benessere)

Key highlights of the analytical validation include, 

The analytical validation was conducted using an automated ELISA analyzer, which significantly enhances both performance and throughput compared to Immunovia's prior IMMray platform as well as standard manual ELISA tests. 

"We are happy to announce that our analytical validation results confirm the strong performance of our next-generation test.  This achievement validates the quality of our analytical method and marks an important milestone to provide a reliable, convenient test that could ultimately improve patient outcomes by enabling early detection of pancreatic cancer. We are excited to be moving to the next phase, clinical validation," says Lisa Ford , Ph.D., Lab Director at Immunovia. 

Following the successful completion of the analytical validation, Immunovia has initiated a large-scale clinical validation study to assess the accuracy of its next-generation test in detecting stage 1 and 2 pancreatic cancer. This clinical validation is expected to be completed by December 2024 . The results will provide crucial insights into the test's clinical performance, including its sensitivity and specificity. 


Jeff Borcherding 
CEO and President 
jeff.borcherding@immunovia.com

Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com  
+46 709 11 56 08

 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA , 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-completes-analytical-validation-of-its-next-generation-pancreatic-cancer-test,c4045832

The following files are available for download:

 

View original content: https://www.prnewswire.co.uk/news-releases/immunovia-completes-analytical-validation-of-its-next-generation-pancreatic-cancer-test-302265346.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili